The relation between cartilage biomarkers (C2C, C1,2C, CS846, and CPII) and the long-term outcome of rheumatoid arthritis patients within the CAMERA trial

Table 4 Association between biomarker values and the long-term outcome measures

		Long-term outcome (5 years after treatment)
		Yearly radiographic progression rate			Time-averaged DAS28
Biomarker		No.	B	95% CI	No.	B	95% CI
C2C	Baseline	126	0.08	-0.28 to 0.44	120	0.11	-0.25 to 0.47
	1 yr	126	-0.23	-0.67 to 0.20	120	0.18	-0.25 to 0.61
	Change	126	-0.59	-1.14 to -0.03	120	0.04	-0.52 to 0.60
C1,2C	Baseline	126	0.47	0.001 to 0.95	120	0.10	-0.40 to 0.60
	1 yr	127	0.14	-0.36 to 0.65	121	0.22	-0.29 to 0.73
	Change	126	-1.00	-1.80 to -0.20	120	0.33	-0.52 to 1.18
CS846	Baseline	127	-0.06	-0.27 to 0.16	121	-0.08	-0.29 to 0.14
	1 yr	126	-0.07	-0.29 to 0.15	120	-0.03	-0.26 to 0.20
	Change	126	-0.01	-0.23 to 0.21	120	0.05	-0.18 to 0.28
CPII	Baseline	124	0.14	-0.07 to 0.35	118	-0.05	-0.26 to 0.17
	1 yr	125	0.13	-0.09 to 0.34	119	0.10	-0.12 to 0.31
	Change	122	-0.07	-0.34 to 0.20	122	0.30	0.02 to 0.57
ZC2C + ZC1,2C	Baseline	125	0.07	-0.02 to 0.17
	1 yr	126	0.01	-0.11 to 0.08
	Change	126	-0.13	-0.22 to -0.04

Biomarkers with B (95% confidence interval (CI)) values, which are shown in Bold type have a P value < 0.05 and have been included in the multiple regression analyses. Biomarkers values were determined at baseline, at 1 year, and the change between 1 year and baseline. Next are the sum and ratio scores (based on Z-values), determined when individual biomarkers had a significant association with the outcome in the initial analysis.
DAS28, disease activity score based on 28 joints; n, number of patients investigated; 95% CI, 95% confidence interval.

ISSN: 1478-6362